- Home
- APM vs ADAP Comparison
APM vs ADAP Comparison
Compare APM & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- ADAP
- Stock Information
- Founded
- APM 2010
- ADAP 2008
- Country
- APM United Kingdom
- ADAP United Kingdom
- Employees
- APM N/A
- ADAP N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- ADAP Health Care
- Exchange
- APM Nasdaq
- ADAP Nasdaq
- Market Cap
- APM 18.9M
- ADAP 21.3M
- IPO Year
- APM 2018
- ADAP 2015
- Fundamental
- Price
- APM $1.55
- ADAP $0.20
- Analyst Decision
- APM
- ADAP Hold
- Analyst Count
- APM 0
- ADAP 6
- Target Price
- APM N/A
- ADAP $1.02
- AVG Volume (30 Days)
- APM 399.9K
- ADAP 97.2M
- Earning Date
- APM 04-30-2025
- ADAP 11-12-2025
- Dividend Yield
- APM N/A
- ADAP N/A
- EPS Growth
- APM N/A
- ADAP N/A
- EPS
- APM N/A
- ADAP N/A
- Revenue
- APM N/A
- ADAP $65,084,999.00
- Revenue This Year
- APM N/A
- ADAP N/A
- Revenue Next Year
- APM N/A
- ADAP $24.70
- P/E Ratio
- APM N/A
- ADAP N/A
- Revenue Growth
- APM N/A
- ADAP N/A
- 52 Week Low
- APM $0.46
- ADAP $0.04
- 52 Week High
- APM $7.49
- ADAP $0.88
- Technical
- Relative Strength Index (RSI)
- APM 41.19
- ADAP 61.92
- Support Level
- APM $1.41
- ADAP $0.15
- Resistance Level
- APM $1.63
- ADAP $0.24
- Average True Range (ATR)
- APM 0.28
- ADAP 0.03
- MACD
- APM -0.08
- ADAP 0.00
- Stochastic Oscillator
- APM 11.87
- ADAP 55.59
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.